Evommune, Inc. Operating Income
Evommune, Inc. (EVMN) reported Operating Income of -$34.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Evommune, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$34.90M.
- Evommune, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$23.95M.
- Evommune, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$29.72M.
- Evommune, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$13.33M.
- Evommune, Inc. operating income (loss) for fiscal 2025 was -$81.07M.
- Evommune, Inc. operating income (loss) for fiscal 2024 was -$70.01M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.90M 10-Q · filed 2026-08-06 | -$58.85M 10-Q · filed 2026-08-06 | -$88.56M derived: sum of 3 quarters · filed 2026-08-06 | -$101.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$23.95M 10-Q · filed 2026-05-07 | -$53.67M derived: sum of 2 quarters · filed 2026-05-07 | -$67.00M derived: sum of 3 quarters · filed 2026-05-07 | -$89.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$29.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$43.04M derived: sum of 2 quarters · filed 2026-03-05 | -$66.04M derived: sum of 3 quarters · filed 2026-08-06 | -$81.07M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$13.33M 10-Q · filed 2025-12-11 | -$36.32M derived: sum of 2 quarters · filed 2026-08-06 | -$51.35M 10-Q · filed 2025-12-11 | -$72.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$22.99M 10-Q · filed 2026-08-06 | -$38.03M 10-Q · filed 2026-08-06 | -$59.48M derived: sum of 3 quarters · filed 2026-08-06 | -$76.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$15.03M 10-Q · filed 2026-05-07 | -$36.49M derived: sum of 2 quarters · filed 2026-05-07 | -$53.00M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$21.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$37.97M derived: sum of 2 quarters · filed 2026-03-05 | -$70.01M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$16.52M 10-Q · filed 2025-12-11 | -$48.56M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |